Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus

Realtime	Geld	Brief	Zeit
	47,085	47,175	03.03.
	42,680	43,115	03.03.

Realtime

Geld

Brief

Zeit

47,085

47,175

03.03.

42,680

43,115

03.03.

Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus

WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary of Roivant Sciences Ltd. (ROIV), and Arbutus Biopharma Corporation (ABUS) to resolve patent litigation related to lipid nanoparticle (LNP) delivery technology used in its COVID-19 vaccine.

Under the agreement, Moderna will make a $950 million payment in July 2026. An additional $1.3 billion payment is contingent on a favorable appellate ruling regarding Section 1498 of U.S. law, which Moderna had argued shields certain government-contracted sales from patent liability.

As part of the settlement, Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications and a covenant not to sue on certain patents, ending all related litigation tied to Moderna's COVID-19 vaccine.

Copyright(c) 2026 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX

Tech-Aktien schwanken – 3 Versorger mit Rückenwind

Die Stimmung an den Märkten hat sich grundlegend gedreht. Während Tech- und KI-Werte zunehmend mit Volatilität und Bewertungsrisiken kämpfen, erleben klassische Versorger ein unerwartetes Comeback. Laut IEA und EIA steigt der globale Strombedarf strukturell weiter, nicht nur wegen E-Mobilität und Wärmepumpen, sondern vor allem durch energiehungrige KI-Rechenzentren. Energie wird damit zur zentralen Infrastruktur des digitalen Zeitalters.

Gleichzeitig rücken in unsicheren Marktphasen stabile Cashflows, solide Bilanzen und regulierte Renditen wieder stärker in den Fokus. Genau hier spielen Versorger ihre Stärken aus: berechenbare Erträge, robuste Nachfrage und hohe Dividenden – Qualitäten, die vielen Wachstumswerten aktuell fehlen.

Nach Jahren im Schatten der Tech-Rallye steigt nun das Interesse an Unternehmen, die Stabilität mit langfristigen Wachstumsthemen wie Netzausbau, Dekarbonisierung und erneuerbaren Energien verbinden.

Im aktuellen Spezialreport stellen wir drei Versorger vor, die defensive Stärke mit attraktivem Potenzial kombinieren.

Jetzt den kostenlosen Report sichern – bevor die nächste Versorgerwelle Fahrt aufnimmt!

Hier klicken

Zeit	Aktuelle Nachrichten
Di	Moderna surges after hours on patent settlement with Arbutus and Genevant
Di	Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus	WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary... ► Artikel lesen
Di	Moderna, Inc.: Moderna Resolves Global Patent Litigation with Arbutus/Genevant	Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026District Court's Section 1498 decision to be appealed to the Federal Circuit... ► Artikel lesen
Di	Arbutus Biopharma Corporation: Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Di	Roivant Sciences: Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Zeit

Aktuelle Nachrichten

Moderna surges after hours on patent settlement with Arbutus and Genevant

Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus

Moderna, Inc.: Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026District Court's Section 1498 decision to be appealed to the Federal Circuit...
► Artikel lesen

Arbutus Biopharma Corporation: Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Roivant Sciences: Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Zeit	Aktuelle Nachrichten
01:26	Moderna Settles Patent Dispute for $US950 Million
00:18	Jefferies reiterates Moderna stock Hold rating after patent deal
Di	Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Di	Moderna surges after hours on patent settlement with Arbutus and Genevant
Di	Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus	WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary... ► Artikel lesen

Zeit

Aktuelle Nachrichten

01:26

Moderna Settles Patent Dispute for $US950 Million

00:18

Jefferies reiterates Moderna stock Hold rating after patent deal

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

Moderna surges after hours on patent settlement with Arbutus and Genevant

Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus